Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Hold” by Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average rating of “Hold” from the five research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.00.

NBTX has been the subject of a number of recent analyst reports. Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Wall Street Zen upgraded Nanobiotix to a “hold” rating in a report on Saturday, October 25th.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Stock Performance

Shares of NBTX opened at $22.13 on Friday. Nanobiotix has a 12-month low of $2.82 and a 12-month high of $30.35. The company has a 50-day moving average of $21.50 and a two-hundred day moving average of $13.26.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.